The main market opportunities for CD38-targeted immunotherapies lie in multiple myeloma treatment, given its high CD38 expression. With successful therapeutics like daratumumab and isatuximab, ...

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden ...

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presen ...

Breast cancer remains a predominant global health challenge for women, with late-stage diagnosis being a key contributor to ...

Discover the essential role of TGF-Beta 1 in cellular regulation, its signaling pathway, and how TGF-β1 antibodies are used ...

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, ...

Droplet Biosciences, a company pioneering the use of lymphatic fluid for advanced clinical diagnostics, announces the online release of a peer-reviewed publication with results of a groundbreaking ...

On November 19, 2025, the Food and Drug Administration granted accelerated approval to Bayer’s (BAYRY) sevabertinib, a kinase inhibitor, for ...

Collaborative work between MD Anderson Cancer Center, Mayo Clinic, and Biocartis demonstrated high concordance of the Idylla™ ...

Biocartis Showcases Growing Impact of Idylla™ Platform at AMP 2025Multiple abstracts and a corporate workshop highlight Idylla™’s growing role in oncology diagnostics Itasca, IL, United States, 14 ...

Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade ...

Breast cancer remains a predominant global health challenge for women, with late-stage diagnosis being a key contributor to its high mortality. This ...